Tislelizumab plus chemotherapy with allergy medicine for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination for advanced lung cancer: an immunotherapy drug (tislelizumab) plus standard chemotherapy, and adds a common allergy medicine (diphenhydramine) to see if it improves outcomes. It's for people who haven't had prior systemic treatment for their lung cancer and are generally healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You need to have advanced or metastatic non-small cell lung cancer (stage IIIB or IV) that hasn't been treated with systemic therapy before.
- Your cancer should not have known EGFR, ALK, or ROS1 mutations (unless you have a specific type like adenocarcinoma with wild-type EGFR and negative ALK).
- You need to be in good physical condition (ECOG score 0 or 1), meaning you can do daily activities and light work.
- You need adequate organ function, such as normal blood counts, liver, kidney, and thyroid function.
- You must not have certain conditions like myasthenia gravis, glaucoma, or prostate problems, and you should not be allergic to diphenhydramine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests a combination of tislelizumab (an immunotherapy drug) with chemotherapy for people with a type of lung cancer that has not spread to other organs and cannot be removed with surgery. The goal is to see if this treatment can shrink tumors and help people live longer.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Hear when a new Advanced and Metastatic NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.